The guideline established by the European Urologic Association in 2015 suggests that antimuscarinics or beta-3-adrenoceptor agonists (B3A) should be used in men with benign prostatic hyperplasia (BPH) for the treatment of moderate-to-severe lower urinary tract symptoms characterized by predominant bladder storage symptoms. This evidence concerns the gene ADRB3 and benign prostatic hyperplasia.